Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)TRAIL receptor pathway to antitumor effects of interferon-α/5-fluorouracil against hepatocellular carcinoma

Tameyoshi Yamamoto, Hiroaki Nagano, Masato Sakon, Hisashi Wada, Hidetoshi Eguchi, Motoi Kondo, Bazarragchaa Damdinsuren, Hideo Ota, Masato Nakamura, Hiroshi Wada, Shigeru Marubashi, Atsushi Miyamoto, Keizo Dono, Koji Umeshita, Shoji Nakamori, Hideo Yagita, Morito Monden

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Purpose: Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNα and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC). Experimental Design: Susceptibility of HCC cell lines to TRAIL and/or 5-FU was examined by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. The effects of 5-FU, IFNα, or both on the expression of TRAIL receptors (R1, R2, R3, and R4) on HCC cells or TRAIL in peripheral blood mononuclear cells (PBMC) were examined by flow cytometry. IFNα-induced cytotoxic effects of PBMC on HCC cell lines were examined by 51Cr release assay. TRAIL expression in peripheral blood mononuclear cells and liver tissue from patients was examined by real-time reverse transcription-PCR or immunohistochemistry. Results: HLE and HepG2 were sensitive to TRAIL, but HuH7, PLC/PRF/5, and HLF were resistant. 5-FU had synergistic effect on TRAIL in HLF and additive effect in four other HCC cell lines. TRAIL receptors on HCC cells were up-regulated by 5-FU, and IFNα induced TRAIL on CD4+ T cells, CD14+ monocytes, and CD56+ NK cells. Treatment of effector cells by IFNα and target HCC cells by 5-FU enhanced the cytotoxicity of CD14+ monocytes and CD56+ NK cells against HCC cells via a TRAIL-mediated pathway. TRAIL mRNA overexpression was noted in PBMC of HCC patients who clinically responded to IFNα/5-FU combination therapy, and TRAIL+ mononuclear cells were found in cancer tissue of a responder. Conclusion: Our results suggest that modulation of TRAIL/TRAIL receptor-mediated cytotoxic pathway might partially contribute to the anti-HCC effect of IFNα and 5-FU combination therapy.

Original languageEnglish
Pages (from-to)7884-7895
Number of pages12
JournalClinical Cancer Research
Volume10
Issue number23
DOIs
Publication statusPublished - Dec 1 2004

Fingerprint

TNF-Related Apoptosis-Inducing Ligand Receptors
Fluorouracil
Interferons
Hepatocellular Carcinoma
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
Blood Cells
Cell Line
Natural Killer Cells
Monocytes
Therapeutics
Reverse Transcription
Flow Cytometry
Research Design
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)TRAIL receptor pathway to antitumor effects of interferon-α/5-fluorouracil against hepatocellular carcinoma. / Yamamoto, Tameyoshi; Nagano, Hiroaki; Sakon, Masato; Wada, Hisashi; Eguchi, Hidetoshi; Kondo, Motoi; Damdinsuren, Bazarragchaa; Ota, Hideo; Nakamura, Masato; Wada, Hiroshi; Marubashi, Shigeru; Miyamoto, Atsushi; Dono, Keizo; Umeshita, Koji; Nakamori, Shoji; Yagita, Hideo; Monden, Morito.

In: Clinical Cancer Research, Vol. 10, No. 23, 01.12.2004, p. 7884-7895.

Research output: Contribution to journalArticle

Yamamoto, T, Nagano, H, Sakon, M, Wada, H, Eguchi, H, Kondo, M, Damdinsuren, B, Ota, H, Nakamura, M, Wada, H, Marubashi, S, Miyamoto, A, Dono, K, Umeshita, K, Nakamori, S, Yagita, H & Monden, M 2004, 'Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)TRAIL receptor pathway to antitumor effects of interferon-α/5-fluorouracil against hepatocellular carcinoma', Clinical Cancer Research, vol. 10, no. 23, pp. 7884-7895. https://doi.org/10.1158/1078-0432.CCR-04-0794
Yamamoto, Tameyoshi ; Nagano, Hiroaki ; Sakon, Masato ; Wada, Hisashi ; Eguchi, Hidetoshi ; Kondo, Motoi ; Damdinsuren, Bazarragchaa ; Ota, Hideo ; Nakamura, Masato ; Wada, Hiroshi ; Marubashi, Shigeru ; Miyamoto, Atsushi ; Dono, Keizo ; Umeshita, Koji ; Nakamori, Shoji ; Yagita, Hideo ; Monden, Morito. / Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)TRAIL receptor pathway to antitumor effects of interferon-α/5-fluorouracil against hepatocellular carcinoma. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 23. pp. 7884-7895.
@article{09793badf9b147c589c51b7e7c248f09,
title = "Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)TRAIL receptor pathway to antitumor effects of interferon-α/5-fluorouracil against hepatocellular carcinoma",
abstract = "Purpose: Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNα and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC). Experimental Design: Susceptibility of HCC cell lines to TRAIL and/or 5-FU was examined by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. The effects of 5-FU, IFNα, or both on the expression of TRAIL receptors (R1, R2, R3, and R4) on HCC cells or TRAIL in peripheral blood mononuclear cells (PBMC) were examined by flow cytometry. IFNα-induced cytotoxic effects of PBMC on HCC cell lines were examined by 51Cr release assay. TRAIL expression in peripheral blood mononuclear cells and liver tissue from patients was examined by real-time reverse transcription-PCR or immunohistochemistry. Results: HLE and HepG2 were sensitive to TRAIL, but HuH7, PLC/PRF/5, and HLF were resistant. 5-FU had synergistic effect on TRAIL in HLF and additive effect in four other HCC cell lines. TRAIL receptors on HCC cells were up-regulated by 5-FU, and IFNα induced TRAIL on CD4+ T cells, CD14+ monocytes, and CD56+ NK cells. Treatment of effector cells by IFNα and target HCC cells by 5-FU enhanced the cytotoxicity of CD14+ monocytes and CD56+ NK cells against HCC cells via a TRAIL-mediated pathway. TRAIL mRNA overexpression was noted in PBMC of HCC patients who clinically responded to IFNα/5-FU combination therapy, and TRAIL+ mononuclear cells were found in cancer tissue of a responder. Conclusion: Our results suggest that modulation of TRAIL/TRAIL receptor-mediated cytotoxic pathway might partially contribute to the anti-HCC effect of IFNα and 5-FU combination therapy.",
author = "Tameyoshi Yamamoto and Hiroaki Nagano and Masato Sakon and Hisashi Wada and Hidetoshi Eguchi and Motoi Kondo and Bazarragchaa Damdinsuren and Hideo Ota and Masato Nakamura and Hiroshi Wada and Shigeru Marubashi and Atsushi Miyamoto and Keizo Dono and Koji Umeshita and Shoji Nakamori and Hideo Yagita and Morito Monden",
year = "2004",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-04-0794",
language = "English",
volume = "10",
pages = "7884--7895",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)TRAIL receptor pathway to antitumor effects of interferon-α/5-fluorouracil against hepatocellular carcinoma

AU - Yamamoto, Tameyoshi

AU - Nagano, Hiroaki

AU - Sakon, Masato

AU - Wada, Hisashi

AU - Eguchi, Hidetoshi

AU - Kondo, Motoi

AU - Damdinsuren, Bazarragchaa

AU - Ota, Hideo

AU - Nakamura, Masato

AU - Wada, Hiroshi

AU - Marubashi, Shigeru

AU - Miyamoto, Atsushi

AU - Dono, Keizo

AU - Umeshita, Koji

AU - Nakamori, Shoji

AU - Yagita, Hideo

AU - Monden, Morito

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Purpose: Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNα and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC). Experimental Design: Susceptibility of HCC cell lines to TRAIL and/or 5-FU was examined by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. The effects of 5-FU, IFNα, or both on the expression of TRAIL receptors (R1, R2, R3, and R4) on HCC cells or TRAIL in peripheral blood mononuclear cells (PBMC) were examined by flow cytometry. IFNα-induced cytotoxic effects of PBMC on HCC cell lines were examined by 51Cr release assay. TRAIL expression in peripheral blood mononuclear cells and liver tissue from patients was examined by real-time reverse transcription-PCR or immunohistochemistry. Results: HLE and HepG2 were sensitive to TRAIL, but HuH7, PLC/PRF/5, and HLF were resistant. 5-FU had synergistic effect on TRAIL in HLF and additive effect in four other HCC cell lines. TRAIL receptors on HCC cells were up-regulated by 5-FU, and IFNα induced TRAIL on CD4+ T cells, CD14+ monocytes, and CD56+ NK cells. Treatment of effector cells by IFNα and target HCC cells by 5-FU enhanced the cytotoxicity of CD14+ monocytes and CD56+ NK cells against HCC cells via a TRAIL-mediated pathway. TRAIL mRNA overexpression was noted in PBMC of HCC patients who clinically responded to IFNα/5-FU combination therapy, and TRAIL+ mononuclear cells were found in cancer tissue of a responder. Conclusion: Our results suggest that modulation of TRAIL/TRAIL receptor-mediated cytotoxic pathway might partially contribute to the anti-HCC effect of IFNα and 5-FU combination therapy.

AB - Purpose: Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNα and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC). Experimental Design: Susceptibility of HCC cell lines to TRAIL and/or 5-FU was examined by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. The effects of 5-FU, IFNα, or both on the expression of TRAIL receptors (R1, R2, R3, and R4) on HCC cells or TRAIL in peripheral blood mononuclear cells (PBMC) were examined by flow cytometry. IFNα-induced cytotoxic effects of PBMC on HCC cell lines were examined by 51Cr release assay. TRAIL expression in peripheral blood mononuclear cells and liver tissue from patients was examined by real-time reverse transcription-PCR or immunohistochemistry. Results: HLE and HepG2 were sensitive to TRAIL, but HuH7, PLC/PRF/5, and HLF were resistant. 5-FU had synergistic effect on TRAIL in HLF and additive effect in four other HCC cell lines. TRAIL receptors on HCC cells were up-regulated by 5-FU, and IFNα induced TRAIL on CD4+ T cells, CD14+ monocytes, and CD56+ NK cells. Treatment of effector cells by IFNα and target HCC cells by 5-FU enhanced the cytotoxicity of CD14+ monocytes and CD56+ NK cells against HCC cells via a TRAIL-mediated pathway. TRAIL mRNA overexpression was noted in PBMC of HCC patients who clinically responded to IFNα/5-FU combination therapy, and TRAIL+ mononuclear cells were found in cancer tissue of a responder. Conclusion: Our results suggest that modulation of TRAIL/TRAIL receptor-mediated cytotoxic pathway might partially contribute to the anti-HCC effect of IFNα and 5-FU combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=9744276046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9744276046&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0794

DO - 10.1158/1078-0432.CCR-04-0794

M3 - Article

C2 - 15585621

AN - SCOPUS:9744276046

VL - 10

SP - 7884

EP - 7895

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -